AXAi-Min Xu

Ai-Min Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ai-Min Xu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Dong-Juan Xing

    A Department of Interventional Oncology ; Renji Hospital; School of Medicine; Shanghai Jiao Tong University ; Shanghai , China

    1 shared publication
  • Jian-Ming Chen

    A Department of Interventional Oncology ; Renji Hospital; School of Medicine; Shanghai Jiao Tong University ; Shanghai , China

    1 shared publication
  • Ming-Hua Zhu

    C Department of Pathology ; Changhai Hospital and Institute of Liver Diseases; Second Military Medical University ; Shanghai , China

    1 shared publication
  • Shao-Juan Gong

    A Department of Interventional Oncology ; Renji Hospital; School of Medicine; Shanghai Jiao Tong University ; Shanghai , China

    1 shared publication
  • Shou-Mei Wang

    A Department of Interventional Oncology ; Renji Hospital; School of Medicine; Shanghai Jiao Tong University ; Shanghai , China

    1 shared publication
  • Shu-Hui Zhang

    Department of Pathology, Shanghai University of Traditional Chinese Medicine Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai, China

    1 shared publication

Latest Publications

  • microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma

    by Wei-Hua Song, Xiao-Jun Feng, Shao-Juan Gong, Jian-Ming Chen, Shou-Mei Wang, Dong-Juan Xing, Ming-Hua Zhu, Shu-Hui Zhang, Ai-Min Xu

    MicroRNAs (miRNAs) are important regulators of tumor development and progression. In this study, we aimed to explore the expression and role of miR-622 in hepatocellular carcinoma (HCC). We found that miR-622 was significantly downregulated in human HCC specimens compared to adjacent noncancerous liver tissues. miR-622 downregulation was significantly associated with aggressive parameters and poor prognosis in HCC. Enforced expression of miR-622 significantly decreased the proliferation and colony formation and induced apoptosis of HCC cells. In vivo studies demonstrated that miR-622 overexpression retarded the growth of HCC xenograft tumors. Bioinformatic analysis and luciferase reporter assays revealed that miR-622 directly targeted the 3′-untranslated region (UTR) of mitogen-activated protein 4 kinase 4 (MAP4K4) mRNA. Ectopic expression of miR-622 led to a significant reduction of MAP4K4 expression in HCC cells and xenograft tumors. Overexpression of MAP4K4 partially restored cell proliferation and colony formation and reversed the induction of apoptosis in miR-622-overexpressing HCC cells. Inhibition of JNK and NF-κB signaling phenocopied the anticancer effects of miR-622 on HCC cells. Taken together, miR-622 acts as a tumor suppressor in HCC and restoration of miR-622 may provide therapeutic benefits in the treatment of HCC.